{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"MountainTAP-30","nct_id":"NCT07076121","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mountaintap-30-nct07076121. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Arm A","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B","type":"EXPERIMENTAL"},{"description":null,"label":"Arm C","type":"PLACEBO_COMPARATOR"},{"description":null,"label":"Arm D","type":"PLACEBO_COMPARATOR"},{"description":null,"label":"Arm E","type":"EXPERIMENTAL"},{"description":null,"label":"Arm F","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-05-03","type":"ESTIMATED"},"conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":470,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Navlimetostat","otherNames":["BMS-986504","MRTX1719"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["Abraxane"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-03","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2029-05-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)","timeFrame":"Up to 3 years after last participant is randomized"},{"measure":"Overall Survival (OS)","timeFrame":"Up to 3 years after last participant is randomized"}],"references":[],"start_date":{"date":"2025-10-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","url":"https://clinicaltrials.gov/study/NCT07076121"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mountaintap-30-nct07076121"}